3-Indoleacetic acid (Standard) serves as an analytically validated reference material for the phytohormone indole-3-acetic acid (IAA). Designed for precision research applications, this auxin-class plant growth regulator modulates fundamental developmental processes including cellular expansion, tissue differentiation, and organ morphogenesis, driving vegetative growth in plant systems.

ChREBPα/14-3-3 regulator-1 (Compound 43) is a selective molecular glue that stabilizes the ChREBP/14-3-3 protein complex with an EC50 of 3.8 μM. By enhancing this interaction, the compound demonstrates cytoprotective effects against glucolipotoxicity in pancreatic β cells while preserving cellular function. These properties position it as a promising investigational tool for type 2 diabetes research.

BRD9 Degrader-2 (Compound B11) is a highly potent and efficient molecular degrader of BRD9, achieving sub-nanomolar degradation activity (DC50 ≤1.25 nM) with maximal degradation exceeding 75%. This compound represents a promising chemical tool for investigating BRD9-dependent oncogenic pathways in cancer research.

AR Degrader-2 (Compound 2) is a molecular glue compound that induces targeted degradation of the androgen receptor (AR), demonstrating potent activity with a DC50 ranging from 0.3 to 0.5 μM in VCaP prostate cancer cells.

rac-Lenalidomide-13C5 is a carbon-13 labeled racemic variant of lenalidomide, designed for tracer studies in pharmacokinetic and metabolic research.

Lenalidomide-13C5,15N is an isotopically labeled analog of lenalidomide (HY-A0003; CC-5013), a thalidomide-derived molecular glue compound. This orally bioavailable immunomodulator functions through selective cereblon (CRBN) E3 ubiquitin ligase engagement, mediating targeted ubiquitination and proteasomal degradation of lymphoid transcription factors IKZF1 and IKZF3 via the CRBN-CRL4 complex. The compound demonstrates dual therapeutic activity by both suppressing proliferation of mature B-cell malignancies (including multiple myeloma) and enhancing T-cell immunostimulation through IL-2 induction.

3-Indoleacetic acid-d4 (Indole-3-acetic acid-d4; 3-IAA-d4) is a deuterium-stabilized isotopologue of the endogenous auxin phytohormone 3-indoleacetic acid (HY-18569). As the predominant natural auxin, 3-IAA regulates fundamental plant growth processes, including cellular elongation and proliferation, when supplemented in plant tissue culture systems.

Antitumor agent-100 (compound A6) hydrochloride is an orally bioavailable molecular glue that selectively targets the PDE3A-SLFN12 complex (IC50 = 0.3 μM). By binding to the PDE3A catalytic pocket, it stabilizes SLFN12 interaction, subsequently inhibiting protein translation and triggering apoptotic cell death. This dual mechanism underlies its potent antitumor activity.

CCT373567 demonstrates potent and selective BCL6 inhibition, exhibiting an IC50 of 2.9 nM in biochemical TR-FRET assays and 25.9 nM in cellular NanoBRET assays. This cell-permeable compound maintains robust activity in physiological settings, highlighting its potential as a targeted therapeutic agent.

GSPT1 degrader-4 (compound 3) functions as a potent molecular glue targeting GSPT1, demonstrating a degradation concentration (DC50) of 25.4 nM. The compound exhibits strong anti-proliferative activity in CAL51 cells with an IC50 value of 39 nM.

FIZ1 degrader 1 (compound 1) represents a novel IMiD-derived molecular glue compound engineered for targeted FIZ1 protein degradation.

BRD9 Degrader-4 (BRD9c) is a highly potent bifunctional molecular glue compound that induces targeted degradation of BRD9, demonstrating exceptional activity with a DC50 value of 25 nM or lower. This degradative capability translates to significant anti-tumor efficacy, highlighting its potential as a therapeutic agent.

Avadomide hydrochloride (CC-122 hydrochloride), the salt form of Avadomide (HY-100507), is an orally bioavailable cereblon-targeting agent that exerts potent antitumor and immunomodulatory effects. By modulating cereblon E3 ubiquitin ligase activity, this compound inhibits the NF-κB signaling pathway and induces G1 phase cell cycle arrest, ultimately triggering apoptosis in PDAC cancer cells.

IPS-06061 is an orally bioavailable molecular glue that mediates targeted degradation of KRAS G12D through formation of a CRBN-KRASG12D-IPS06061 ternary complex, demonstrating potent activity with a DC50 below 500 nM.

Lenalidomide hydrochloride (CC-5013 hydrochloride), a thalidomide-derived molecular glue, functions as an orally bioavailable immunomodulatory agent. By binding to the ubiquitin E3 ligase cereblon (CRBN), it recruits the CRBN-CRL4 complex to induce selective ubiquitination and degradation of lymphoid transcription factors IKZF1 and IKZF3. This mechanism underlies its potent activity against mature B-cell malignancies, including multiple myeloma, while also stimulating IL-2 secretion from T cells.

The R-enantiomer of thalidomide, (R)-(+)-thalidomide, exhibits sedative effects distinct from its racemic counterpart.

Cyclosporin A (Cyclosporine A) is a potent immunosuppressive agent commonly administered after allogeneic organ transplants to suppress immune system activity and prevent rejection.

CDO1 Degrader-1 (Compound 8) is a molecular glue that targets cysteine dioxygenase (CDO1) for degradation.

HuR Degrader 2 (Compound 3) is a molecular glue that targets the RNA-binding protein HuR, degrading ~30% of HuR at 0.1 μM. It inhibits the proliferation of Colo-205 cancer cells with an IC50 ≤ 200 nM and exhibits high cereblon binding affinity, as evidenced by an HTRF ratio < 0.02.

Asukamycin, a macrolide polyketide derived from Streptomyces nodosus subsp. asukaensis, exhibits dual antimicrobial and antitumor activities. This natural product demonstrates broad-spectrum antibiotic properties while selectively inhibiting tumor cell proliferation through caspase-8/3-mediated apoptosis induction.

Thalidomide-piperazine hydrochloride represents a chemically modified derivative of the prototypic immunomodulatory drug, featuring a piperazine moiety that enhances solubility while preserving the compound's unique biological properties.

Cyclosporin A acetate-d4 is a deuterium-enriched analog of the cyclic undecapeptide immunosuppressant, featuring four strategic deuterium substitutions that improve metabolic stability while preserving its dual mechanism of action.

Lenalidomide-d5 is a deuterium-enriched analog of the clinically validated immunomodulator ​lenalidomide (CC-5013), featuring five strategic deuterium substitutions that improve metabolic stability while preserving its molecular glue mechanism.

Thalidomide-d4 is a deuterium-enriched analog of the prototypic immunomodulatory drug thalidomide, featuring four strategically positioned deuterium substitutions. This isotopically labeled compound retains the parent molecule's ability to bind cereblon (CRBN) with high affinity (Kd ≈ 250 nM), thereby modulating the activity of the CUL4-RBX1-DDB1-CRBN E3 ubiquitin ligase complex.

Jasmonic acid ((-)-Jasmonic acid) is a plant growth regulator and a derivative of α-Linolenic acid (HY-N0728). Jasmonic acid signaling can also induce the MAP kinase cascade pathway, calcium channel, and many processes that interact with signaling molecules.

Thalidomide-NH-CBP/p300 ligand 2 (P-007) represents a novel PROTAC architecture that simultaneously targets CBP and p300 for proteasomal degradation.

MMH1-NR is a purpose-designed negative control compound for the DCAF16-based BRD4 degrader MMH1, featuring a strategically incorporated non-reactive ethyl group that abolishes degradation activity while maintaining structural similarity.

Pomalidomide-d3 is a stable isotope-labeled analog of the clinically important immunomodulatory drug Pomalidomide, where three hydrogen atoms are replaced with deuterium.

BTX-7312 is a cereblon-based SOS1 bifunctional degrader and a molecular glue. BTX-7312 reduces downstream signaling markers pERK and pS6 and shows antiproliferative activity in various KRAS-mutated cells.

BRD4 Degrader-1 (Compound ML 1-50) represents a novel class of monovalent, covalent molecular glues that selectively degrade bromodomain-containing protein 4 (BRD4) through an E3 ligase-dependent mechanism. Unlike traditional bivalent PROTACs, this compound utilizes a unique covalent binding strategy to recruit the DCAF16 E3 ubiquitin ligase, inducing potent degradation of both BRD4 long (BRD4-L) and short (BRD4-S) isoforms in cellular systems.